Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02531295 · ClinicalTrials.gov registry record · Phase 1
Immunologic Response to Kansui in Treated HIV+ Individuals: a Dose Escalation Study
A Phase 1 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT02531295 is a Phase 1 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 5 participants.
The verdict
NCT02531295, a Phase 1 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and bioactivity of an herbal supplement called "kansui," which contains several active ingredients such as ingenols that may have a role in helping clear HIV from the body. Kansui has been used in traditional Chinese medicine for centuries to treat various ailments such as for eliminating excess fluid in the abdomen or lungs, loosening phlegm from the chest, and relieving constipation. Based on preliminary in vitro data from our group, kansui extract powder is a potent activator of HIV transpcription in latently infected Jurkat cells. The investigators' hypothesis is that kansui extract powder prepared as tea will be safe and well-tolerated, elicit an in vivo immunologic response, and at the doses administered, increase HIV transcription in latently-infected cells among HIV-infected patients on suppressive antiretroviral therapy.
Interventions
- DRUG Euphorbia kansui extract powder prepared as tea
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2019-05-15 |
| Est. Completion | 2020-03-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02531295
The ClinicalTrials.gov registry entry for NCT02531295 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Euphorbia kansui extract powder prepared as tea is the first listed.
NCT02531295 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02531295 about?
NCT02531295 is a clinical study titled "Immunologic Response to Kansui in Treated HIV+ Individuals: a Dose Escalation Study". The purpose of this study is to determine the safety and bioactivity of an herbal supplement called "kansui," which contains several active ingredients such as ingenols that may have a role in helping clear HIV from the body. Kansui has been used in traditional Chinese medicine for centuries to trea...
What is the current status of trial NCT02531295?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2019-05-15. Estimated completion is 2020-03-19.
What interventions are being tested in trial NCT02531295?
The interventions under investigation include: Euphorbia kansui extract powder prepared as tea (DRUG).
Who is sponsoring clinical trial NCT02531295?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.